COVID-19 vaccine development has facilitated through unparalleled collaboration in the pharmaceutical industry and between governments. The geographic distribution of COVID-19 vaccine development puts North American entities having about 40% of the activity compared to 30% in Asia and Australia, 26% in Europe, and a few projects in South America and Africa
The safety requirements for COVID-19 vaccines are the same as for any other vaccine and will not be lowered in the context of the pandemic. After development, the vaccines will continue to be carefully monitored for safety and effectiveness
Title : Drug Delivery to Stem Cells in Regenerative Medicine
Esmaiel Jabbari, University of South Carolina, USA
Title : Targeted nanoparticles for diagnostic and theranostic applications
Paul Millner, University of Leeds, UK
Title : Nanostructured Formulations in Skin Cancer: Challenges and Perspectives
Daniela Monti, University of Pisa, Italy
Title : Introducing the Sorush Cancer Treatment Protocol (SCTP)
Sorush Niknamian, Violet Cancer Institute, USA
Title : Hydrogen Sulfide: A Stinky Gas….. and Novel Therapeutic Target for Inflammatory Disease
Madhav Bhatia, University of Otago, Newzealand
Title : Assessment an umbilical cells induced neuroplasticity in patients with schizophrenia using functional MRI
Dmitry Ustyuzhanin, National Medical Research Center of Cardiology, Russia
Title : Evaluation of drug permeability in blood-brain barrier in vitro models
Anna Caprifico, Kingston University, UK
Title : Bryophyllum pinnatum Compounds Inhibit the Oxytocin-Induced Pathways in Human Myometrial Cells
Stefanie Santos, University Hospital Zurich, Switzerland
Title : Cancer: is there any hope?
Ranjita Shegokar, Capnomed GmbH, Germany
Title : Process innovation in the production of smart lipid-polymeric release systems
Annalisa Dalmoro, University of Salerno, Italy